98%
921
2 minutes
20
Introduction: Cardiac transplantation has progressed markedly since 1967, with advances in immunosuppression, surgical techniques, and postoperative care that improve outcomes. However, challenges persist in the Middle East and North Africa (MENA) region due to unique cultural, economic, and infrastructural barriers. This review explores the status, innovations, and challenges of cardiac transplantation within MENA countries, comparing outcomes with global standards.
Methodology: A comprehensive literature search was conducted across PubMed, Web of Science, and Cochrane databases, including studies from inception to May 2024. Search terms targeted heart transplantation practices, challenges, and innovations in the MENA region. Articles not in English, non-human studies, and duplicates were excluded. Data extraction focused on patient demographics, transplantation outcomes, and barriers specific to the MENA context.
Results: Cardiac transplantation in MENA has made strides, with established programs in Saudi Arabia, the UAE, and Lebanon. Innovations like ex-vivo perfusion and Left Ventricular Assist Devices (LVAD) are improving transplant outcomes, yet organ shortages remain critical. Cultural and religious beliefs influence donation rates, and infrastructure varies widely, with disparities in healthcare resources across countries. Key barriers include low donor registration, inconsistent brain death definitions, and limited public awareness. Economic and infrastructure limitations further complicate access to advanced transplantation techniques.
Conclusion: While cardiac transplantation has evolved in MENA, significant barriers hinder widespread adoption. Enhancing public awareness, developing regional networks, and implementing standardized protocols can improve outcomes. Targeted immunosuppressive therapies and continued innovation in organ preservation are essential to advance cardiac transplantation in MENA.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cpcardiol.2024.102920 | DOI Listing |
J Thorac Cardiovasc Surg
September 2025
, Michael E. DeBakey Department of Surgery, Division of Cardiothoracic Transplantation and Circulatory Support, Baylor College of Medicine, Houston, Texas, USA; , Department of Regenerative Medicine Research, Texas Heart Institute, Houston, Texas, USA. Electronic address:
Objective: Celsior solution (CS) is used for cold preservation of hearts from brain death donors but not for those from circulatory death donors (DCD). Plasma membrane repair proteins are crucial for maintaining myocardial integrity during ischemia. We compared the effects of CS cold preservation with normal saline (NS) on myocardial membrane disruption and pyroptosis in human DCD hearts, with varying warm ischemia times (WIT) and cold storage durations.
View Article and Find Full Text PDFHum Immunol
September 2025
Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
Heart transplant candidates that are highly sensitized against human leukocyte antigens (HLA) face ongoing challenge in finding immunologically compatible donors. Desensitization strategies aimed at reducing HLA antibody titers have variable success rates. Imlifidase, a novel immunoglobulin G-degrading enzyme derived from Streptococcus pyogenes has been successfully used to eliminate pre-formed antibodies in sensitized kidney transplant recipients.
View Article and Find Full Text PDFJ Allergy Clin Immunol
September 2025
National Heart and Lung Institute, Imperial College London, London, United Kingdom; Frankland and Kay Allergy Centre, UK NIHR Imperial Biomedical Research Centre, United Kingdom.
Recent advancements in genomics and "omic" technologies have ushered in a transformative era referred to as personalized or precision medicine. This innovative approach considers the unique genetic profiles of individuals, along with a range of variability factors, to devise tailored disease treatments and prevention strategies that cater to the distinct needs of each patient. Although the terms personalized medicine and precision medicine are frequently utilized interchangeably, it is essential to delineate the subtle distinctions between them.
View Article and Find Full Text PDFJ Heart Lung Transplant
September 2025
Professor of Pediatrics and Immunology, Director Pediatric Cardiac Transplantation, University of Alberta / Stollery Children's Hospital, 4C2.24, Walter MacKenzie Center, 8440 - 112 Street, Edmonton, AB, T6G 2B7. Electronic address:
Am J Med Sci
September 2025
Division of Gastroenterology and Hepatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Background: Metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis is now the second leading indication for liver transplantation (LT) worldwide and is associated with increased risk of cardiovascular events before and after LT. Cirrhotics who undergo left heart catheterization (LHC) with coronary artery stenting for LT evaluation require dual-antiplatelet therapy (DAPT). Data regarding the safety, risk of gastrointestinal (GI) bleeding, and mortality risk of cirrhotics receiving DAPT is limited.
View Article and Find Full Text PDF